P2Y12 Inhibitors [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.

==== P2Y12 Inhibitors ====

P2Y12 inhibitors are a class of **antiplatelet medications** that block the **P2Y12 receptor** on platelets, preventing platelet aggregation and reducing the risk of thrombotic events such as heart attacks and strokes.

===== Examples of P2Y12 Inhibitors =====
  * **Clopidogrel** – A prodrug requiring hepatic activation, commonly used in preventing cardiovascular events.
  * **Prasugrel** – More potent than clopidogrel, with a faster onset and greater efficacy but higher bleeding risk.
  * **Ticagrelor** – A reversible inhibitor that does not require metabolic activation, offering a more predictable response.
  * **Cangrelor** – An intravenous P2Y12 inhibitor used in acute settings for rapid platelet inhibition.

===== Clinical Uses of P2Y12 Inhibitors =====
  * **Acute Coronary Syndromes (ACS)** – Used to prevent clot formation in patients with unstable angina or myocardial infarction.
  * **Percutaneous Coronary Intervention (PCI)** – Administered alongside aspirin to reduce thrombotic complications post-stent placement.
  * **Secondary Stroke Prevention** – Sometimes used in combination with aspirin for short-term dual antiplatelet therapy (DAPT).